Global Health Innovative Technology (GHIT) Fund
Active Since: 2013
Contributing to SDGs…
Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.
Global Health Innovation Technology Fund.
Academia or research institute
Drugs for Neglected Diseases initiative (DNDi)
Liverpool School of Tropical Medicine
Bio21 Molecular Science and Biotechnology Institute
Global Alliance for TB Drug Development (TB Alliance)
Intergovernmental Organizations and Multilaterals
Private foundation or development organization
Bill and Melinda Gates Foundation
Professional and trade associations
Established in 2013, Global Health Innovative Technology (GHIT) is a Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.
Globalization and the unprecedented speed of cross-border infection in the 21st century has created the need for a global health strategy. Awareness of common global threats to the health of citizens has increased, and governments understand the need to work together to counteract these threats. Since 2000, the global community has focused on three of the biggest threats to human health – HIV, tuberculosis and malaria.
The GHIT Fund was established by three key partners: the Government of Japan, the Bill & Melinda Gates Foundation and five Japanese leading pharmaceutical companies: Astellas Pharma, Daiichi Sankyo, Eisai, Shionogi, and Takeda Pharmaceutical. In 2018, there are now 11 full partners.
As the world’s first public-private partnership, GHIT Fund has facilitated research and development for neglected diseases, such as malaria, tuberculosis and NTDs. As antimicrobial resistance is also now a serious global health threat, GHIT supports AMR related projects. The combination of Japan’s government and its drug industry—the third largest in the world—brings Japan’s technology, innovation and insights to the development of drugs, vaccines and diagnostics for the developing world.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.2: Reduce Under-5 Mortality
- 3.3: Communicable Diseases & NTDs
- 3.4: NCDs (including mental health)
SDG 5: Gender Equality
SDG 10: Reduced Inequalities
SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
In 2016, GHIT Fund announced it was investing in a vaccine that could block the transmission of two species of malaria and a rapid fire test that can reveal a malaria infection in a matter of minutes. It is also investing in the development of a new diagnostic test for tuberculosis (TB) by Fujifilm Corporation and Foundation for Innovative New Diagnostics, which can diagnose TB in HIV-positive patients.
In 2015 the GHIT Fund, its members Eisai, Shionogi and Takeda Pharmaceutical, along with partners the Drugs for Neglected Diseases initiative (DNDi) and AstraZeneca began a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
In 2013 Astellas received a $1.86 million grant to develop and register a new pediatric formulation of the gold standard treatment drug praziquantel to combat schistosomiasis.
In June 2013, with support from the GHIT Fund, Takeda began to work with Product Development Partners (PDPs), including MMV, TB Alliance and DNDi, in a program to screen Takeda’s drug compound library for new candidate compounds that might have the potential to be developed into new drugs for the treatment of infections particularly prevalent in developing countries, such as HIV, tuberculosis, malaria and neglected tropical diseases.
GHIT has provided grants of $5.7 million to six global partnerships developing innovative drugs and vaccines against malaria, tuberculosis and Chagas disease in the first round of request for proposal (RFP) in November, 2013. Another $12 million grants for TB and NTDs were awarded to four innovative projects in the second round of RFP in March, 2014.
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)
Neglected Tropical Diseases (NTDs)
- Chagas Disease
- Dengue and Chikungunya
- Cardiovascular Diseases
- Respiratory Diseases
- Mental & Neurological Disorders
- General Noncommunicable Disease Care (Health System)
- Other NCD